IPSEN (OTCMKTS:IPSEY) Shares Gap Up – Here’s Why

IPSEN (OTCMKTS:IPSEY)’s stock price gapped up prior to trading on Tuesday . The stock had previously closed at $45.03, but opened at $47.5650. IPSEN shares last traded at $47.5650, with a volume of 142 shares trading hands.

Analyst Ratings Changes

A number of brokerages have recently weighed in on IPSEY. HC Wainwright restated a “buy” rating on shares of IPSEN in a research note on Tuesday, June 30th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of IPSEN in a research report on Thursday, May 14th. Zacks Research raised IPSEN to a “hold” rating in a research report on Friday, May 29th. Finally, Jefferies Financial Group downgraded IPSEN from a “hold” rating to a “moderate sell” rating in a research note on Sunday, August 2nd. Two equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold”.

IPSEN Price Performance

The stock’s 50 day simple moving average is $45.85 and its two-hundred day simple moving average is $46.04.

About IPSEN

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).